Drug intelligence / Profile preview

Lo-medus

Development stage: Unknown
Lead developer: AVN Ayurveda Formulations
Administration: Oral

Overview

Lo-medus is a polyherbal Ayurvedic formulation developed by AVN Ayurveda Formulations for the management of lipid disorders and cardiovascular health. It is composed of several traditional medicinal plants, including Commiphora mukul (Guggulu), Tinospora cordifolia (Amruta), and Pterocarpus marsupium (Asana), along with incinerated iron (Loha bhasma). The formulation is primarily indicated for hyperlipidemia, hypercholesterolemia, dyslipidemia, atherosclerosis, and obesity. Its mechanism of action involves regulating lipid levels through FXR (farnesoid X receptor)-mediated enhanced bile acid clearance, increasing HDL cholesterol, and providing antioxidant effects to prevent lipid peroxidation and reduce blood viscosity.

Brand names: Lo-medusLomedus

Targets

FXR (Farnesoid x-activated receptor)

Beyond the preview

Go deeper on Lo-medus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lo-medus.

Explore the full profile